TxCell Completes a E10.5M Second Round and Initiates Clinical Trials

TxCell Completes a E10.5M Second Round and Initiates Clinical Trials


Sophia Antipolis, March 5th, 2008 – TxCell, a specialty biopharmaceutical firm developing novel cell therapies for autoimmune and chronic inflammatory diseases, today announced that it had raised €10.5 million in a second round of financing. In 2007, the AFSSAPS (the French Agency for Health Product Safety) authorized the company to start its first clinical trial of a Tr1 lymphocyte-based therapy in Crohn’s disease. This round of financing confirms the significant potential of TxCell’s innovative approach and will enable the company to determine the clinical efficacy of treatment with autologous Tr1 cells.

This second round, led by TxCell’s longstanding investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Seventure, will allow the company to progress its development programs on Crohn’s disease (OvasaveTM), rheumatoid arthritis (CellArthrixTM) and a number of orphan diseases.

“This fundraising testifies to the confidence that TxCell’s longstanding investors have placed in our company and confirms the great potential of this cell therapy approach (based on the biological properties of Tr1 regulatory lymphocytes) for the treatment of autoimmune and chronic inflammatory diseases”, commented Frédéric Hammel, CEO of TxCell.

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.